These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 18778555)

  • 1. Minocycline for preventing EGFR inhibitor-induced rash.
    Loprinzi CL
    Curr Oncol Rep; 2008 Jul; 10(4):303. PubMed ID: 18778555
    [No Abstract]   [Full Text] [Related]  

  • 2. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
    Melosky B; Anderson H; Burkes RL; Chu Q; Hao D; Ho V; Ho C; Lam W; Lee CW; Leighl NB; Murray N; Sun S; Winston R; Laskin JJ
    J Clin Oncol; 2016 Mar; 34(8):810-5. PubMed ID: 26573073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
    Goto A; Ozawa Y; Koda K; Akahori D; Koyauchi T; Amano Y; Kakutani T; Sato Y; Hasegawa H; Matsui T; Yokomura K; Suda T
    Respir Investig; 2018 Mar; 56(2):179-183. PubMed ID: 29548657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
    Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan
    Chen L; Brown J; Marmaduke DQ; Mayo C; Grau G; Lau YK; Obasaju CK
    Support Care Cancer; 2018 Jul; 26(7):2369-2377. PubMed ID: 29423677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
    Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
    J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
    Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
    Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash.
    Vaubel J; Livingstone E; Schadendorf D; Zimmer L
    J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1685-9. PubMed ID: 24422792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
    Parmar S; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seeringer A; Paul T; Seufferlein T; Stingl JC
    Pharmacogenomics J; 2013 Apr; 13(2):181-8. PubMed ID: 22158333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug rash, eosinophilia, and systemic symptoms syndrome: Two pediatric cases demonstrating the range of severity in presentation--A case of vancomycin-induced drug hypersensitivity mimicking toxic shock syndrome and a milder case induced by minocycline.
    Vinson AE; Dufort EM; Willis MD; Eberson CP; Harwell JI
    Pediatr Crit Care Med; 2010 Jul; 11(4):e38-43. PubMed ID: 20407399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced hypersensitivity syndrome due to minocycline complicated by severe myocarditis.
    Kanno K; Sakai H; Yamada Y; Iizuka H
    J Dermatol; 2014 Feb; 41(2):160-2. PubMed ID: 24471460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients
.
    Iimura Y; Shimomura H; Yasu T; Imanaka K; Ogawa R; Ito A; Suzuki K; Yamaguchi G; Kawasaki N; Konaka C
    Int J Clin Pharmacol Ther; 2018 Nov; 56(11):551-554. PubMed ID: 30232957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minocycline prevents gentamicin-induced ototoxicity by inhibiting p38 MAP kinase phosphorylation and caspase 3 activation.
    Wei X; Zhao L; Liu J; Dodel RC; Farlow MR; Du Y
    Neuroscience; 2005; 131(2):513-21. PubMed ID: 15708492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minocycline-induced serum sickness.
    Levenson T; Masood D; Patterson R
    Allergy Asthma Proc; 1996; 17(2):79-81. PubMed ID: 8934798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lupus-like disease due to minocycline].
    Marai I; Shoenfeld Y
    Harefuah; 2002 Feb; 141(2):151-2, 223, 222. PubMed ID: 11905086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minocycline-induced rash in an 18-year-old patient.
    Karofsky PS; Williams GP
    Arch Pediatr Adolesc Med; 1995 Feb; 149(2):217-8. PubMed ID: 7849889
    [No Abstract]   [Full Text] [Related]  

  • 18. [Minocycline-induced lupus erythematodes].
    Egger SS; Studer IG; Rätz Bravo AE; Krähenbühl S
    Praxis (Bern 1994); 2006 Aug; 95(35):1297-303. PubMed ID: 16970139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minocycline-induced lupus. A systematic review.
    Schlienger RG; Bircher AJ; Meier CR
    Dermatology; 2000; 200(3):223-31. PubMed ID: 10828631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal hyperpigmentation from prophylactic minocycline for EGFR inhibitor.
    Imafuku K; Natsuga K; Aoyagi S; Shimizu H
    J Eur Acad Dermatol Venereol; 2016 Apr; 30(4):690-2. PubMed ID: 25627561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.